Search

We previously demonstrated pharmacokinetic differences among manufacturing batches of a US Food and Drug Administration (FDA)-approved dry powder inhalation product (Advair Diskus 100/50) large enough to establish between-batch bio-inequivalence. Here, we provide independent confirmation of pharmacokinetic bio-inequivalence among Advair Diskus 100/50 batches, and quantify residual and between-batch variance component magnitudes. These variance estimates are used to consider the type I error rate of the FDA's current two-way crossover design recommendation. When between-batch pharmacokinetic variability is substantial, the conventional two-way crossover design cannot accomplish the objectives of FDA's statistical bioequivalence test (i.e., cannot accurately estimate the test/reference ratio and associated confidence interval). The two-way crossover, which ignores between-batch pharmacokinetic variability, yields an artificially narrow confidence interval on the product comparison. The unavoidable consequence is type I error rate inflation, to ∼25%, when between-batch pharmacokinetic variability is nonzero. This risk of a false bioequivalence conclusion is substantially higher than asserted by regulators as acceptable consumer risk (5%).

We previously demonstrated pharmacokinetic differences among manufacturing batches of a US Food and Drug Administration (FDA)-approved dry powder inhalation product (Advair Diskus 100/50) large enough to establish between-batch bio-inequivalence. Here, we provide independent confirmation of pharmacokinetic bio-inequivalence among Advair Diskus 100/50 batches, and quantify residual and between-batch variance component magnitudes. These variance estimates are used to consider the type I error rate of the FDA's current two-way crossover design recommendation. When between-batch pharmacokinetic variability is substantial, the conventional two-way crossover design cannot accomplish the objectives of FDA's statistical bioequivalence test (i.e., cannot accurately estimate the test/reference ratio and associated confidence interval). The two-way crossover, which ignores between-batch pharmacokinetic variability, yields an artificially narrow confidence interval on the product comparison. The unavoidable consequence is type I error rate inflation, to ∼25%, when between-batch pharmacokinetic variability is nonzero. This risk of a false bioequivalence conclusion is substantially higher than asserted by regulators as acceptable consumer risk (5%).

We report experimental studies to understand the reaction mechanism of the intermetallic anode Cu2Sb with Na and demonstrate that it is capable of retaining about 250 mAh g-1 over 200 cycles when using fluoroethylene carbonate additive. X-ray diffraction data indicate during the first discharge the reaction leads to the formation of crystalline Na 3Sb via an intermediate amorphous phase. Upon desodiation the Na 3Sb reverts to an amorphous phase, which then recrystallizes into Cu2Sb at full charge, indicating a high degree of structural reversibility. The structure after charging to 1 V is different from that of Cu2Sb, as indicated by X-ray absorption spectroscopy and 121Sb Mössbauer spectroscopy, and is due to the formation of an amorphous Na-Cu-Sb phase. At full discharge, an isomer shift of -8.10 mm s -1 is measured, which is close to that of a Na3Sb reference powder (-7.95 mm s-1) and in agreement with the formation of Na3Sb domains. During charge, the isomer shift at 1 V (-9.29 mm s-1) is closer to that of the pristine material (-9.67 mm s -1), but the lower value is consistent with the lack of full desodiation, as expected from the potential profile and the XAS data. © 2014 American Chemical Society.